Please login to the form below

Not currently logged in
Email:
Password:

MediCity names David Browning as director

Will head the UK collaboration between Alliance Boots and Nottingham-based biocluster BioCity

MediCity David Browning A new collaboration between pharmacy chain Alliance Boots and the Nottingham-based biocluster BioCity took a step forward this week with the appointment of David Browning as director.

MediCity is a subsidiary of BioCity and is based on the Alliance Boots site within the Nottingham Enterprise Zone. It aims to provide start-ups in the health and wellness sector with office and laboratory space.

Browning joins the new venture from healthcare consultancy Paragreen Associates where he served as managing director.

His past experience in healthcare includes a VP role within the healthcare business of Philips and four years as CEO of nanotechnology specialist Oxonica Healthcare.

During this period in charge of Oxonica, Browning worked with Alliance Boots to launch Optisol, an active ingredient in suncare products.

His new role sees him once again working with Alliance Boots, with the company contributing access to innovation and product development knowledge and supply chain expertise to companies involved in MediCity.

Browning's first task in charge is to oversee the refurbishment and population of MediCity's base in Nottingham, before leading the call for tenants to take up space.

“I grew up in the East Midlands and I am looking forward to working with talented innovators of new clinical and consumer products,” he said.

“We will draw on a network of business, financial and technical experts, as well as Alliance Boots experience, to help them commercialise their ideas.”

16th October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics